EMERYVILLE, Calif., Feb. 22 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.
The data demonstrated that amantadine, ribavirin and oseltamivir, when administered as components of a triple combination therapy, had a synergistic effect (i.e. enhanced antiviral activity) against multiple amantadine- and oseltamivir-resistant virus strains. The data also demonstrated that the antiviral activity of the TCAD regimen is greater than the antiviral activity of any double combination. Further, when investigating amantadine-resistant virus strains against which amantadine had no significant antiviral activity as a single agent, the addition of amantadine at clinically relevant concentrations to the combination of ribavirin and oseltamivir resulted in a dose dependent inhibition of virus replication. This was similarly observed for oseltamivir in strains that were oseltamivir resistant. These data demonstrate that the TCAD therapy may have broad-spectrum activity against the circulating resistant influenza A strains, including novel influenza A/H1N1, the pandemic influenza strain.
About TCAD
Adamas is pioneering triple combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points in the virus proliferation pathway. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (R) (oseltamivir phosphate, Roche). Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, act synergistically to provide a much higher level of antiviral activity than single or double drug combination therapies. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. TCAD therapy for influenza A is currently being investigated in a Phase 2 human clinical study.
CONTACT: Kimberly Kraemer, Corporate Communications, Adamas
Pharmaceuticals, +1-510-450-3572
Web site: http://www.adamaspharma.com/
